Cancer Immunology, Immunotherapy

, Volume 61, Issue 6, pp 839–854

Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate “Natural” and “Inducible” CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer

  • Mark J. Dobrzanski
  • Kathleen A. Rewers-Felkins
  • Khaliquzzaman A. Samad
  • Imelda S. Quinlin
  • Catherine A. Phillips
  • William Robinson
  • David J. Dobrzanski
  • Stephen E. Wright
Original article

DOI: 10.1007/s00262-011-1128-x

Cite this article as:
Dobrzanski, M.J., Rewers-Felkins, K.A., Samad, K.A. et al. Cancer Immunol Immunother (2012) 61: 839. doi:10.1007/s00262-011-1128-x

Abstract

Adoptive T cell therapy for cancer patients optimally requires participation of CD4 T cells. In this phase I/II study, we assessed the therapeutic effects of adoptively transferred IL-10- and IFN-γ-producing CD4 effector cells in patients with recurrent ovarian cancer. Using MUC1 peptide and IL-2 for ex vivo CD4 effector cell generation, we show that three monthly treatment cycles of autologous T cell restimulation and local intraperitoneal re-infusion-modulated T cell-mediated immune responses that were associated with enhanced patient survival. One patient remains disease-free, another patient experienced prolonged survival for nearly 16 months with recurrent disease, and two patients expired within 3–5 months following final infusion. Prolonged survivors showed elevated levels of systemic CD3+CD4+CD25+ and CD3+CD4+CD25 T cells when compared to that of pre-treatment levels and similarly treated short-term survivors. Such cell populations among these patients contained variable levels of “Inducible” Tr1 (CD4+CD25FoxP3IL-10+) and “Natural” (CD4+CD25+CD45RO+FoxP3+) TReg cell numbers and ratios that were associated with prolonged and/or disease-free survival. Moreover, peptide-restimulated T cells from these patients showed an elevation in both IFN-γ production, memory cell phenotype, and select TNF family ligands associated with enhanced T cell survival and apoptosis-inducing activities. This suggests that intraperitoneally administered Th1-like cells, producing elevated levels of IL-10, may require and/or induce differential levels of distinct systemic TReg subpopulations that influence, in part, long-term tumor immunity and enhanced memory/effector CD4-mediated therapeutic potentials. Furthermore, treatment efficacy and enhanced memory cell phenotype did not appear to be dependent on TReg cell numbers but upon ratios of “Inducible” and “Natural” TReg subpopulations.

Keywords

Tumor immunityRegulatory T cellsTh1 effector cellsTNF superfamilyT effector/memory cellsAdoptive T cell immunotherapyIL-10IFN-γRecurrent ovarian cancer

Abbreviations

Th1

CD4+ T cells producing IFN-γ

TReg

Regulatory T cells

Foxp3

Forkhead box protein p3

TR1

CD4+ CD25FoxP3 T cells producing IL-10

nTRegs

Ag-experienced natural TReg CD4+CD25+CD45RO+FoxP3 cells

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Mark J. Dobrzanski
    • 1
    • 5
  • Kathleen A. Rewers-Felkins
    • 1
  • Khaliquzzaman A. Samad
    • 1
  • Imelda S. Quinlin
    • 1
  • Catherine A. Phillips
    • 1
    • 2
  • William Robinson
    • 3
    • 4
  • David J. Dobrzanski
    • 5
  • Stephen E. Wright
    • 1
    • 2
  1. 1.Department of Internal MedicineTexas Tech University School of MedicineAmarilloUSA
  2. 2.Amarillo Veterans Affairs Health Care SystemAmarilloUSA
  3. 3.Harrington Cancer CenterAmarilloUSA
  4. 4.Department of Obstetrics and GynecologySchool of Medicine, Texas Tech University Health Science CenterAmarilloUSA
  5. 5.Clinical Research DepartmentBristol Hospital Cancer Care CenterBristolUSA